187 related articles for article (PubMed ID: 37486517)
1. Using CRISPR/Cas9 to Edit a Thyroid Cancer Cell Line.
Fuziwara CS; Kimura ET
Adv Exp Med Biol; 2023; 1429():73-84. PubMed ID: 37486517
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Highly Expressed microRNA miR-146b with CRISPR/Cas9n Gene Editing System in Thyroid Cancer.
Santa-Inez DC; Fuziwara CS; Saito KC; Kimura ET
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360757
[TBL] [Abstract][Full Text] [Related]
3. Application of CRISPR-Cas9 for Long Noncoding RNA Genes in Cancer Research.
Zhen S; Li X
Hum Gene Ther; 2019 Jan; 30(1):3-9. PubMed ID: 30045635
[TBL] [Abstract][Full Text] [Related]
4. Identification of Novel Insulin Resistance Related ceRNA Network in T2DM and Its Potential Editing by CRISPR/Cas9.
Matboli M; Kamel MM; Essawy N; Bekhit MM; Abdulrahman B; Mohamed GF; Eissa S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360895
[TBL] [Abstract][Full Text] [Related]
5. In Vivo CRISPR/Cas9-Based Targeted Disruption and Knockin of a Long Noncoding RNA.
Cheng X; Peters ST; Pruett-Miller SM; Saunders TL; Joe B
Methods Mol Biol; 2021; 2254():305-321. PubMed ID: 33326084
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer.
Huang LC; Tam KW; Liu WN; Lin CY; Hsu KW; Hsieh WS; Chi WM; Lee AW; Yang JM; Lin CL; Lee CH
Dis Markers; 2018; 2018():3835783. PubMed ID: 29849821
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-mediated noncoding RNA editing in human cancers.
Yang J; Meng X; Pan J; Jiang N; Zhou C; Wu Z; Gong Z
RNA Biol; 2018 Jan; 15(1):35-43. PubMed ID: 29028415
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
[TBL] [Abstract][Full Text] [Related]
9. Genetic Editing of Long Noncoding RNA Using CRISPR/Cas9 Technology.
Larter K; Yi B; Xi Y
Methods Mol Biol; 2021; 2372():169-177. PubMed ID: 34417751
[TBL] [Abstract][Full Text] [Related]
10. Emerging Role of CRISPR/Cas9 Technology for MicroRNAs Editing in Cancer Research.
Aquino-Jarquin G
Cancer Res; 2017 Dec; 77(24):6812-6817. PubMed ID: 29208606
[TBL] [Abstract][Full Text] [Related]
11. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
[TBL] [Abstract][Full Text] [Related]
12. Marek's Disease Virus-Encoded MicroRNA 155 Ortholog Critical for the Induction of Lymphomas Is Not Essential for the Proliferation of Transformed Cell Lines.
Zhang Y; Tang N; Luo J; Teng M; Moffat K; Shen Z; Watson M; Nair V; Yao Y
J Virol; 2019 Sep; 93(17):. PubMed ID: 31189706
[TBL] [Abstract][Full Text] [Related]
13. Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment.
Jiang C; Meng L; Yang B; Luo X
Clin Genet; 2020 Jan; 97(1):73-88. PubMed ID: 31231788
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 small promoter deletion in H19 lncRNA is associated with altered cell morphology and proliferation.
da Silva Santos R; Pinheiro DP; Teixeira LPR; Sales SLA; Dos Santos Luciano MC; de Lima Melo MM; Pinheiro RF; Tavares KCS; Furtado GP; Pessoa C; Furtado CLM
Sci Rep; 2021 Sep; 11(1):18380. PubMed ID: 34526543
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment.
Liu B; Saber A; Haisma HJ
Drug Discov Today; 2019 Apr; 24(4):955-970. PubMed ID: 30849442
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA HIT000218960 promotes papillary thyroid cancer oncogenesis and tumor progression by upregulating the expression of high mobility group AT-hook 2 (HMGA2) gene.
Li T; Yang XD; Ye CX; Shen ZL; Yang Y; Wang B; Guo P; Gao ZD; Ye YJ; Jiang KW; Wang S
Cell Cycle; 2017 Jan; 16(2):224-231. PubMed ID: 27929737
[TBL] [Abstract][Full Text] [Related]
17. Thyroid Follicular Cell Loss of Differentiation Induced by MicroRNA miR-17-92 Cluster Is Attenuated by CRISPR/Cas9n Gene Silencing in Anaplastic Thyroid Cancer.
Fuziwara CS; Saito KC; Kimura ET
Thyroid; 2020 Jan; 30(1):81-94. PubMed ID: 31578932
[No Abstract] [Full Text] [Related]
18. Long Non-Coding RNAs in Thyroid Cancer: Implications for Pathogenesis, Diagnosis, and Therapy.
Mahmoudian-Sani MR; Jalali A; Jamshidi M; Moridi H; Alghasi A; Shojaeian A; Mobini GR
Oncol Res Treat; 2019; 42(3):136-142. PubMed ID: 30799425
[TBL] [Abstract][Full Text] [Related]
19. An efficient CRISPR/Cas9 platform for targeted genome editing in rose (Rosa hybrida).
Wang C; Li Y; Wang N; Yu Q; Li Y; Gao J; Zhou X; Ma N
J Integr Plant Biol; 2023 Apr; 65(4):895-899. PubMed ID: 36460630
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA LINC00313 modulates papillary thyroid cancer tumorigenesis via sponging miR-4429.
Wu WJ; Yin H; Hu JJ; Wei XZ
Neoplasma; 2018 Nov; 65(6):933-942. PubMed ID: 29940766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
